Clinical Trial Update: RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome [Phase 2]

View source ↗

Summary

This Phase 2 dose-finding trial of dabigatran etexilate in patients with acute coronary syndrome has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Coronary Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-02-11